Skip to main content
SpringerLink
Log in

Antineoplastics/furosemide

Lack of efficacy and tumour lysis syndrome: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kikuchi S, et al. Massive hyperphosphatemia in clinical tumor lysis syndrome during prophylactic rasburicase use: risk factors and treatment options. International Cancer Conference Journal 12: 69-74, No. 1, 28 Oct 2022. Available from: URL: http://doi.org/10.1007/s13691-022-00580-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antineoplastics/furosemide. Reactions Weekly 1971, 39 (2023). https://doi.org/10.1007/s40278-023-45164-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-45164-z

Search

Navigation